Brown Nicholas F, Carter Thomas, Kitchen Neil, Mulholland Paul
Department of Oncology, University College London Hospitals, 250 Euston Road, London, NW1 2PG, UK.
UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6DD, UK.
CNS Oncol. 2017 Oct;6(4):291-296. doi: 10.2217/cns-2017-0006. Epub 2017 Oct 6.
BRAFV600E mutations have been identified in a number of glioma subtypes, most frequently in pleomorphic xanthoastrocytoma, ganglioglioma, pilocytic astrocytoma, and epithelioid glioblastoma. Although the development of BRAF inhibitors has dramatically improved the clinical outcome for patients with BRAFV600E mutant tumors, resistance develops in a majority of patients due to reactivation of the MAPK pathway. Addition of MEK inhibition to BRAF inhibition improves survival. Here we report successful treatment of two patients with BRAFV600E mutant pleomorphic xanthoastrocytoma using the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib.
在多种胶质瘤亚型中已鉴定出BRAFV600E突变，最常见于多形性黄色星形细胞瘤、节细胞胶质瘤、毛细胞型星形细胞瘤和上皮样胶质母细胞瘤。尽管BRAF抑制剂的开发显著改善了BRAFV600E突变肿瘤患者的临床结局，但由于MAPK通路的重新激活，大多数患者会产生耐药性。在BRAF抑制的基础上加用MEK抑制可提高生存率。在此，我们报告了使用BRAF抑制剂达拉非尼联合MEK抑制剂曲美替尼成功治疗两名BRAFV600E突变多形性黄色星形细胞瘤患者的病例。
